# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Active fund managers making large bets on momentum plays indicate confidence that Big Tech's rally has legs for the remaind...
Cantor Fitzgerald analyst Louise Chen reiterates Eli Lilly and Co (NYSE:LLY) with a Overweight and maintains $885 price target.
Novo Nordisk's Saxenda study published in JAMA Network Open reveals significant declines in bone density among patients, ra...
Eli Lilly collaborates with Microsoft-backed OpenAI to leverage generative AI for developing novel antimicrobials targeting dru...
Cantor Fitzgerald analyst Louise Chen reiterates Eli Lilly and Co (NYSE:LLY) with a Overweight and maintains $885 price target.
Eli Lilly and Company (NYSE:LLY) announced a collaboration with OpenAI that will allow Lilly to leverage OpenAI's generativ...